ppt jurnal 3 das-mri
Post on 02-Apr-2018
237 Views
Preview:
TRANSCRIPT
-
7/27/2019 Ppt Jurnal 3 DAS-MRI
1/25
PresenterDr. M. Dasawarsa. R
Moderator
Dr. Ratih krisna, Sp.OG (K)
-
7/27/2019 Ppt Jurnal 3 DAS-MRI
2/25
Pre-eclampsia/eclampsia is one of the most
common causes of maternal and perinatal
morbidity and mortality in low and middleincome countries
Magnesium sulfate is the drug of choice for
prevention of seizures as part of
comprehensive management of the disease
-
7/27/2019 Ppt Jurnal 3 DAS-MRI
3/25
To determine whether the published literature
from low-and middle-income countries
supports the concern about the safety of use ofmagnesium sulfate
-
7/27/2019 Ppt Jurnal 3 DAS-MRI
4/25
An integrative review of the literature was
conducted to document the known incidences
of severe adverse reactions to magnesiumsulfate, and specific outcomes of interest
related to its use
MEDLINE (via PubMed), Embase, and the
Cochrane. Searches were limited to the years
1980 through February 2012
-
7/27/2019 Ppt Jurnal 3 DAS-MRI
5/25
Inclusion criteria
Magnesiumsulfate was usedto manage pre-eclampsia or
eclampsia in aprospectiveclinical study
The study wasconducted in a
low-or middle-income country
The studyincluded the
recording of theincidence of any
adverse sideeffect resulting
from magnesiumsulfate use
-
7/27/2019 Ppt Jurnal 3 DAS-MRI
6/25
Exclusion criteria
The study had beenconducted in high-incomecountries (where treatmentand monitoring approaches
may differ)
Did not specifically recordthe incidence of side
effects related tomagnesium sulfate use
-
7/27/2019 Ppt Jurnal 3 DAS-MRI
7/25
-
7/27/2019 Ppt Jurnal 3 DAS-MRI
8/25
-
7/27/2019 Ppt Jurnal 3 DAS-MRI
9/25
-
7/27/2019 Ppt Jurnal 3 DAS-MRI
10/25
-
7/27/2019 Ppt Jurnal 3 DAS-MRI
11/25
-
7/27/2019 Ppt Jurnal 3 DAS-MRI
12/25
-
7/27/2019 Ppt Jurnal 3 DAS-MRI
13/25
-
7/27/2019 Ppt Jurnal 3 DAS-MRI
14/25
-
7/27/2019 Ppt Jurnal 3 DAS-MRI
15/25
-
7/27/2019 Ppt Jurnal 3 DAS-MRI
16/25
-
7/27/2019 Ppt Jurnal 3 DAS-MRI
17/25
-
7/27/2019 Ppt Jurnal 3 DAS-MRI
18/25
-
7/27/2019 Ppt Jurnal 3 DAS-MRI
19/25
-
7/27/2019 Ppt Jurnal 3 DAS-MRI
20/25
-
7/27/2019 Ppt Jurnal 3 DAS-MRI
21/25
The findings demonstrate that across all theincluded studies the adverse effects that areoften of concern to providers occur infrequently,
and that when adverse effects occurred, delay ofrepeat administration was generally sufficient tomitigate the effect.
While every maternal death is regrettable,maternal mortality directly attributable to theuse of magnesium sulfate reported in thesestudies was extremely rare.
-
7/27/2019 Ppt Jurnal 3 DAS-MRI
22/25
1. Are the represented sample have
the same condition regarding their
disease?
Yes
2. Are sample followed up
completely and prolonged?
No, they not followed
up completely and
prolonged
3. Are result criteria got blinded? Not mention
-
7/27/2019 Ppt Jurnal 3 DAS-MRI
23/25
4. If subgroup found with different
prognosis, are they performed
adjustment on important prognostic
factors ?
Yes
5. How about result tendency on
certain duration ?
Yes
6. How accurate prognostic
prediction?
P < 0.05
-
7/27/2019 Ppt Jurnal 3 DAS-MRI
24/25
7. Could you applicate valid
important prognostic evidence from
your patient?Yes
8. Are patients on your study as
same as patient at your clinical
practice ?Yes
9. Are important clinical evidenceaffect your conclusion for advising or
explaining your patient ?
Yes
-
7/27/2019 Ppt Jurnal 3 DAS-MRI
25/25
top related